New research applying advanced statistical methods, has been able to identify new potential therapeutic targets: ST2 and CSF-1, which show casual association with the risk of developing IBD and could simultaneously serve as prognostic biomarkers and targets for future therapies. Here, CSF1 is linked to inflammatory bowel disease.